11:00am Chair Introduction

Nicole Paulk, Associate Professor, University of California, San Francisco

11:05am Presentation: Capsid Engineering to Overcome the Bottleneck of AAV Gene Therapy

• AAV gene therapy limited by tropism, immunogenicity, and manufacturability
• Discovery of next generation AAV through capsid engineering
• Addressing the challenges of capsid engineering

Li Ou, Vice President, Genemagic Bio

11:20am Presentation: Process C: OXBs Latest Lentiviral Vector Platform Process for Improved Yield and Quality

• Process C, including the benefits afforded by perfusion-based upstream production coupled with enhanced downstream processing
• OXBs innovative technology toolbox – a range of new technologies that result in increased productivity and improved purity – collectively enabling the successful delivery of viral vectors for future life-saving therapies and improved access of cost-effective therapies to patients
• OXBs recently approved innovative solution for GMP viral vector fill finish

James Miskin, Chief Technical Officer, Oxford Biomedica

11:35am Presentation: Reshape Viral Vector Manufacturing Through Flexible Platform 

• The impact of preliminary process evaluation to the success of a viral vector-based product
• How right-first-time approach allows to fast-track process development and reach production scale quickly
• Improve safety and productivity through smart optimization tools, like DoE

Hanna Lesch, Chief Technology Officer, Exothera

11:50am Closing Panel with Q&A

All Session Participants